National Scleroderma Foundation leadership is aware of the pause in two CAR-T clinical development programs and is closely following developments.
For people living with scleroderma, particularly those with severe disease and limited treatment options, emerging approaches such as CAR-T and other cellular therapies have generated much-needed hope. We recognize that news of a clinical trial pause can therefore be deeply concerning to people living with scleroderma, their families and care partners.
Safety must always be the first priority in clinical research. It is important that investigators, regulators, and trial sponsors fully evaluate the available information, understand what occurred, and determine the appropriate path forward.
At the same time, we would caution against drawing broader conclusions about CAR-T therapy, and other cellular therapies, or their potential in scleroderma based on a single clinical development. Scleroderma remains a disease with significant unmet need, and continued rigorous research into CAR-T and other innovative approaches is essential.
While the National Scleroderma Foundation does not endorse specific drugs, treatments or clinical trials, we regularly provide educational information about clinical research and emerging therapies, including CAR-T. That content is developed with medical and scientific experts and informed by people with lived experience, and is provided strictly for educational purposes.
Clinical research is an important and ongoing conversation within the scleroderma community. People living with scleroderma and their families closely follow advances in research because there is an urgent need for better treatments and, ultimately, a cure. There is tremendous interest in clinical trial participation, but also a clear need for patients to have reliable information to help them make informed decisions.
Our role is to help people understand clinical trials broadly: what questions to ask, how to weigh potential benefits and risks, where to find trusted information, and why it is important to work closely with their own health care providers when considering whether a particular study is appropriate for them.
Whenever a safety concern emerges in a clinical trial, our community pays close attention.
We are still learning about the circumstances surrounding these pauses, and it would be premature to speculate about what they may mean. We will continue to follow the information as it becomes available, advocate for clear and timely communication with the patient community, and support the rigorous research needed to advance new treatment options for people living with scleroderma.
